Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
OptiBiotix’s SlimBiome shows hunger reduction effects in new study
LONDON - OptiBiotix Health plc (AIM:OPTI) announced Wednesday that a new peer-reviewed study on its SlimBiome product has been published in the European Journal of Nutrition.
The double-blind placebo-controlled study found that a single 3g dose of SlimBiome significantly reduced insulin levels, hunger, and desire to eat while increasing feelings of fullness, according to the company’s press release statement.
The research, led by Adele Costabile, Professor of Clinical Nutrition and the Microbiome at the University of Roehampton, will be presented at the 18th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health scheduled for June 24-26.
OptiBiotix stated that these findings align with previous published studies, consumer studies, and customer feedback showing that SlimBiome reduces hunger and food cravings.
The company reported that the study was conducted to support health claims for appetite regulation and hunger control in products for a leading U.S. weight management brand, referenced in an April 15 announcement.
According to OptiBiotix, the company now has both acute and long-term studies in healthy, overweight, and obese individuals, which have enabled it to make on-pack health claims in multiple markets including Europe, Australia/New Zealand, India, Asia, Canada, and the USA.
Stephen O’Hara, CEO of OptiBiotix Health, was quoted saying the study adds further evidence demonstrating SlimBiome’s efficacy in reducing hunger and food cravings, leading to changes in the amount and type of food people eat.
OptiBiotix describes itself as a life sciences business developing products that reduce hunger and food cravings, enhance the gut microbiome, and provide sweet fibers as healthy sugar substitutes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.